BMB Reports · 2019 · 10 citations · 32 references
MedicineOncologyPharmacologyCancer PharmacologyEpigeneticsMolecular OncologyCancer CytogeneticsCancer EpigeneticsChromatinEpigenetic Alterations In CancerEpigenetic Regulation In CancerMalignant NeoplasmsAnticancer ActivityAnticancer ChemotherapyCancer Cell Proliferation InhibitionCentrosome BiologyCentrosome OrganizationCervical Cancer ChemotherapyDna Methylation ModulationEpigenetic Therapies
Methylation is a primary epigenetic mechanism regulating gene expression. 5-aza-2'-deoxycytidine is an FDA-approved drug prescribed for treatment of cancer by inhibiting DNA-Methyl-Transferase 1 (DNMT1). Results of this study suggest that prolonged treatment with 5-aza-2'-deoxycytidine could induce centrosome abnormalities in cancer cells and that CEP131, a centrosome protein, is regulated by DNMT1. Interestingly, cancer cell growth was attenuated in vitro and in vivo by inhibiting the expression of Cep131. Finally, Cep131-deficient cells were more sensitive to treatment with DNMT1 inhibitors. These findings suggest that Cep131 is a potential novel anti-cancer target. Agents that can inhibit this protein may be useful alone or in combination with DNMT1 inhibitors to treat cancer. [BMB Reports 2019; 52(5): 342-347].
32
MethPrimer: designing primers for methylation PCRs
Long-Cheng Li, Rajvir Dahiya · Bioinformatics · 2002 · 2.8K citations · Full text